Summit Therapeutics Inc. Adjustments For Unrealised Foreign Exchange Losses Gains
Summit Therapeutics Inc. (SMMT) reported Adjustments For Unrealised Foreign Exchange Losses Gains of -GBP 2.75 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2020-06-02
- Summit Therapeutics Inc. adjustments for unrealised foreign exchange losses gains for the quarter ending 2020-03-31 was -2.75M GBP.
- Summit Therapeutics Inc. adjustments for unrealised foreign exchange losses gains for the quarter ending 2019-10-31 was 1.22M GBP.
- Summit Therapeutics Inc. adjustments for unrealised foreign exchange losses gains for the quarter ending 2019-07-31 was -1.17M GBP.
- Summit Therapeutics Inc. adjustments for unrealised foreign exchange losses gains for the quarter ending 2019-04-30 was -154.00K GBP.
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 3 month | Adjustments For Unrealised Foreign Exchange Losses Gains 6 month | Adjustments For Unrealised Foreign Exchange Losses Gains 9 month | Adjustments For Unrealised Foreign Exchange Losses Gains 11 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month |
|---|---|---|---|---|---|
| 2020-03-31 | -2.75M GBP 6-K · filed 2020-06-02 | ||||
| 2019-12-31 | 544.00K GBP 20-F · filed 2020-04-30 | ||||
| 2019-10-31 | 1.22M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | 51.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -103.00K GBP 6-K · filed 2019-12-17 | ||
| 2019-07-31 | -1.17M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -1.32M GBP 6-K · filed 2019-10-11 | |||
| 2019-04-30 | -154.00K GBP 6-K · filed 2019-06-12 | ||||
| 2019-03-31 | 691.00K GBP 6-K · filed 2020-06-02 | ||||
| 2019-01-31 | 648.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 431.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 49.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | -408.00K GBP 20-F · filed 2020-04-30 | |
| 2018-10-31 | -217.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -599.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -1.06M GBP 6-K · filed 2019-12-17 | 34.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-07-31 | -382.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -839.00K GBP 6-K · filed 2019-10-11 | 251.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 127.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-04-30 | -457.00K GBP 6-K · filed 2019-06-12 | 633.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 509.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.03M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-01-31 | 1.09M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 966.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | 1.49M GBP derived: sum of 3 quarters · filed 2020-04-30 | 1.96M GBP 20-F · filed 2020-04-30 | |
| 2017-10-31 | -124.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | 397.00K GBP derived: sum of 2 quarters · filed 2018-12-11 | 870.00K GBP 6-K · filed 2018-12-11 | ||
| 2017-07-31 | 521.00K GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | 994.00K GBP 6-K · filed 2018-09-20 | |||
| 2017-04-30 | 473.00K GBP 6-K · filed 2018-06-05 | ||||
| 2017-01-31 | 711.00K GBP 20-F · filed 2019-03-29 | ||||
| 2016-01-31 | -169.00K GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |